Stock Track | Argenx SE Surges 5.75% Pre-Market on Stellar Q3 Earnings Beat

Stock Track

Oct 30, 2025

Shares of Argenx SE (NASDAQ: ARGX) soared 5.75% in pre-market trading on Thursday, following the release of the company's impressive third-quarter financial results that surpassed analyst expectations across the board.

The biopharmaceutical company reported quarterly earnings per share (EPS) of $5.18, handily beating the analyst consensus estimate of $4.30 by 20.44%. This represents a remarkable 272.66% increase from the $1.39 per share reported in the same period last year, showcasing the company's strong financial growth.

Argenx's top-line performance was equally impressive, with quarterly sales reaching $1.151 billion. This figure not only exceeded the analyst consensus estimate of $1.056 billion by 8.97% but also marked a substantial 95.46% year-over-year increase from $588.878 million. The robust sales growth underscores the company's successful commercialization efforts and increasing market penetration for its products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1117828768"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117828768\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117828768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117828768","market":"sg","top_or_hot":-1,"title":"Stock Track | Argenx SE Surges 5.75% Pre-Market on Stellar Q3 Earnings Beat","media":"Stock Track","content":"<p>Shares of Argenx SE (NASDAQ: ARGX) soared 5.75% in pre-market trading on Thursday, following the release of the company's impressive third-quarter financial results that surpassed analyst expectations across the board.</p>\n\n<p>The biopharmaceutical company reported quarterly earnings per share (EPS) of $5.18, handily beating the analyst consensus estimate of $4.30 by 20.44%. This represents a remarkable 272.66% increase from the $1.39 per share reported in the same period last year, showcasing the company's strong financial growth.</p>\n\n<p>Argenx's top-line performance was equally impressive, with quarterly sales reaching $1.151 billion. This figure not only exceeded the analyst consensus estimate of $1.056 billion by 8.97% but also marked a substantial 95.46% year-over-year increase from $588.878 million. The robust sales growth underscores the company's successful commercialization efforts and increasing market penetration for its products.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Argenx SE Surges 5.75% Pre-Market on Stellar Q3 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Argenx SE Surges 5.75% Pre-Market on Stellar Q3 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-30 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Argenx SE (NASDAQ: ARGX) soared 5.75% in pre-market trading on Thursday, following the release of the company's impressive third-quarter financial results that surpassed analyst expectations across the board.</p>\n\n<p>The biopharmaceutical company reported quarterly earnings per share (EPS) of $5.18, handily beating the analyst consensus estimate of $4.30 by 20.44%. This represents a remarkable 272.66% increase from the $1.39 per share reported in the same period last year, showcasing the company's strong financial growth.</p>\n\n<p>Argenx's top-line performance was equally impressive, with quarterly sales reaching $1.151 billion. This figure not only exceeded the analyst consensus estimate of $1.056 billion by 8.97% but also marked a substantial 95.46% year-over-year increase from $588.878 million. The robust sales growth underscores the company's successful commercialization efforts and increasing market penetration for its products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1117828768","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117828768","pubTimestamp":1761811814,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Argenx SE (NASDAQ: ARGX) soared 5.75% in pre-market trading on Thursday, following the release of the company's impressive third-quarter financial results that surpassed analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"股票追踪|Argenx SE因第三季度盈利出色而盘前飙升5.75%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"Shares of Argenx SE (NASDAQ: ARGX) soared 5.75% in pre-market trading on Thursday, following the release of the company's impressive third-quarter financial results that surpassed analyst expectations across the board.\nThe biopharmaceutical company reported quarterly earnings per share (EPS) of $5.18, handily beating the analyst consensus estimate of $4.30 by 20.44%. This represents a remarkable 272.66% increase from the $1.39 per share reported in the same period last year, showcasing the company's strong financial growth.\nArgenx's top-line performance was equally impressive, with quarterly sales reaching $1.151 billion. This figure not only exceeded the analyst consensus estimate of $1.056 billion by 8.97% but also marked a substantial 95.46% year-over-year increase from $588.878 million. The robust sales growth underscores the company's successful commercialization efforts and increasing market penetration for its products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}